Evidence map›Paper›PMID 21920941›Full record

ArticleHuman molecular genetics2011

Losing balance: Hardy-Weinberg disequilibrium as a marker for recurrent loss-of-heterozygosity in cancer.

Katherine Wilkins, Thomas LaFramboise

Abstract read
In one paragraph

Article in Human molecular genetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Katherine WilkinsDepartment of Genetics, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA.
Thomas LaFramboise

Funding

A genomic survey of allele-specific selection in tumor ampliconsR01CA131341 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI LAFRAMBOISE, THOMAS LOUIS, PE'ER, ITSHACK G · 2008 to 2011
$1.2M
NCI NIH HHS CA131341NCI NIH HHS R01 CA131341Wellcome Trust
6 · The paper itself

Abstract

Identifying regions of loss-of-heterozygosity (LOH) in a tumor sample is a challenging problem. State-of-the-art computational approaches can infer LOH from single-nucleotide polymorphism (SNP) array data, but calling precise boundaries is complicated by normal-cell contamination and markers that are homozygous in the germline and therefore non-informative. More recently, the focus has shifted to pinpointing the loci recurrently affected by LOH events across multiple tumors. Recurrent LOH regions often harbor genes important for tumor suppression. Here, we propose a method that infers LOH rates across an entire sample set on an SNP-by-SNP basis. Our method achieves this by leveraging the straightforward principle that, by definition, LOH depletes heterozygotes, thereby disrupting Hardy-Weinberg equilibrium. We apply a statistical test for such LOH-influenced disruptions, and derive a maximum-likelihood estimator for the LOH rate based on the observed number of heterozygotes. This accounts for LOH in both its hemizygous deletion and copy-neutral forms, and does not make use of matched normal genotypes. Power simulations show high levels of sensitivity for the statistical test, and application to a control normal-tissue data set demonstrates a low false-discovery rate. We apply the method to three large publicly available tumor SNP array data sets, where it is able to localize tumor-suppressor gene targets of the LOH events. Inferred LOH rates are quite concordant across platforms/laboratories and between cell lines and tumors, but in a tumor type-dependent fashion. Finally, we produce rate estimates that are generally higher than previously published, and provide evidence that the latter are likely underestimates.

Indexed as

Biomarkers, TumorCell Line, TumorDatabases, GeneticFalse Positive ReactionsGenes, Tumor SuppressorGenome, HumanHumansLikelihood FunctionsLinkage DisequilibriumLoss of HeterozygosityNeoplasmsReceptor-Like Protein Tyrosine Phosphatases, Class 2Biomarkers, TumorPTPRD protein, humanReceptor-Like Protein Tyrosine Phosphatases, Class 2

Identifiers

PMID21920941
PMCPMC3221535

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.